MIK665 free base · Synonyms: S-64315

MIK665 is a special Mcl-1 inhibitor.

For research use only. Not for human or veterinary use.

Target Bcl-2 Family

Research area Cancer

Purity >98% Stock Inquire

MIK665 structure

CAS No.: 1799631-75-6

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
50 mg	USD 850.00	BP-02347-50mg	In stock	Get quote
100 mg	USD 1,200.00	BP-02347-100mg	In stock	Get quote
250 mg	USD 1,800.00	BP-02347-250mg	In stock	Get quote
500 mg	USD 2,500.00	BP-02347-500mg	In stock	Get quote
1 g	Inquire	BP-02347-1g	In stock	Inquire
2 g	Inquire	BP-02347-2g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

MIK665 (S-64315) is a special Mcl-1 inhibitor with an IC50 of 1.81 nM.

Biological activity

MIK665 is an inhibitor of induced myeloid leukemia cell differentiation protein (Mcl-1; Bcl2-L-3), with potential pro-apoptotic and antineoplastic activities. MIK665 binds to and inhibits the activity of Mcl-1, which promotes apoptosis of cells overexpressing Mcl-1. Mcl-1, an anti-apoptotic protein belonging to the Bcl-2 family of proteins, is upregulated in cancer cells and promotes tumor cell survival.

Identifiers

SMILES: COC1=CC=CC=C1C1=NC(COC2=C(C[C@@H](OC3=C4C(SC(=C4C4=C(C)C(Cl)=C(OCCN5CCN(C)CC5)C=C4)C4=CC=C(F)C=C4)=NC=N3)C(O)=O)C=CC=C2)=CC=N1
InChIKey: PKYIMGFMRFVOMB-LDLOPFEMSA-N

Specifications

MW (average): 875.4050
Formula: C₄₇H₄₄ClFN₆O₆S
CAS No.: 1799631-75-6
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO >100mg/mL; Insoluble in water

Documents

CoA On request
Handling Instructions

References

[1]. Mukherjee N, et al. Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. Cancers (Basel). 2020;12(8):2182. Published 2020 Aug 5.

[2]. Zoltán SZLÁVIK, et al. New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them. WO2016207225A1.

Same target

Search Bcl-2 Family

Same research area

Search Cancer